Abstract
COVID-19 disease is associated with elevated risk of thrombosis, but lab assessment of hypercoagulability of fibrinolysis using conventional clotting assays is challenging. Rotational thromboelastometry (ROTEM) can detect subtle changes in clotting activity and has been used to demonstrate longitudinal coagulopathy in COVID over time. However, typical ROTEM channels including EXTEM and INTEM are affected by anticoagulant use. Un-activated native ROTEM with addition of heparinase (NaHEPTEM) should be a more accurate marker given the multiple anticoagulant protocols in use during COVID-19 treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
